RxDoctor Payments Data

Heloise Westbrook, MD

Interventional Pain Medicine · Madisonville, KYNPI 1952413015

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,223 of the $6,463 with a category attached, or 65.3%. 14 manufacturers reported payments, led by Medtronic at 51.5% of the total. Reporting peaked in 2019 at $4,984 and has fallen 87.1% since, to $645 in 2025.

$6,463in general payments, 2019–2025

Across 84 payments — averaging $76.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$1K
  • Stryker$848
  • Stimwave Technologies Incorporated$543
  • Nevro Corp.$461
  • GRT US Holding, Inc.$76
  • plus $200 from 8 others

What the payments were for

  • Travel & lodging$4,22365%
  • Food & beverage$2,24135%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,463 in reported general payments places this provider in the 70th percentile of 55 interventional pain medicine providers in Kentucky.

See all interventional pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$21,839
Medicare patients
57
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen837$28,401
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen949$19,352
MovantikNaloxegol Oxalate33$14,120
NucyntaTapentadol Hcl13$13,102
Gabapentin743$9,492
Fentanyl66$8,085
Buprenorphine13$5,358
Pregabalin141$3,216
Oxycodone Hcl91$1,814
Tizanidine Hcl210$1,553
Morphine Sulfate ErMorphine Sulfate51$1,367
Lidocaine17$1,207
Hydromorphone Hcl46$958
Methadone Hcl35$659
Morphine Sulfate11$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta$24$13,10213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 interventional pain medicine providers in Kentucky.

Other interventional pain medicine in Madisonville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →